Five cases of Plasmodium vivax malaria treated with artemisinin derivatives: the advantages of a unified approach to treatment

Research output: Contribution to journalArticle


Objectives: In endemic countries with a high level of chloroquine resistance, Plasmodium vivax malaria is associated with high morbidity and mortality. In these areas, the dihydroartemisinin–piperaquine combination resulted in clinical response, a more rapid clearance of parasitaemia, compared to chloroquine therapies, and reduction of recrudescence or reinfection. Methods: We describe five cases of Plasmodium vivax malaria in returning travelers treated with dihydroartemisinin–piperaquine. Results: All patients showed the early parasite clearance and no side effects. Our preliminary results suggest that the dihydroartemisinin–piperaquine combination is effective and safe even in imported cases. Conclusions: A unified treatment policy using the artemisinin combination therapy should be adopted even in non-endemic countries and larger studies are underway to support this strategy.

Original languageEnglish
Pages (from-to)655-659
Number of pages5
Publication statusPublished - Jan 1 2019



  • Artemisinin combination therapy (ACT)
  • Chloroquine resistance
  • Imported malaria
  • Plasmodium vivax

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this